Vitamin D Supplementation for Treatment of Heart Failure
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/7/2015 |
| Start Date: | October 2010 |
| Contact: | Barry E Bleske, Pharm. D |
| Email: | bbleske@umich.edu |
| Phone: | 734-764-5341 |
D suppLementation In HearT FaiLure (DELIGHTFUL)
The central objective of this proposal is to establish that vitamin D supplementation in
heart failure patients with low vitamin D levels will have improved outcomes compared to
placebo. In addition the investigators will also evaluate the role of genetics in regard to
vitamin D and heart failure. The investigators will be evaluating what is currently a novel
approach of identifying patients with low vitamin D and treating this low vitamin D level.
The investigators will be able to evaluate the importance of vitamin D supplementation in
these patients and the role of genetics on our defined outcomes.
heart failure patients with low vitamin D levels will have improved outcomes compared to
placebo. In addition the investigators will also evaluate the role of genetics in regard to
vitamin D and heart failure. The investigators will be evaluating what is currently a novel
approach of identifying patients with low vitamin D and treating this low vitamin D level.
The investigators will be able to evaluate the importance of vitamin D supplementation in
these patients and the role of genetics on our defined outcomes.
Inclusion Criteria:
- HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an
LVEF <40% using nuclear ventriculography or echocardiography within the last 6
months.
- Attempts should have been made at optimizing medical therapy and the participant
should be stable on these medications for at least 3 months.
- Patients with a 25(OH)D level between 10-25 ng/ml
Exclusion Criteria:
- Inability to give informed consent
- Patients with sarcoidosis or other granulomatous disease that can alter vitamin D
metabolism
- Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF
- Renal dysfunction defined as serum creatinine > 2.5 mg/dl
- Pregnant women
- Patients <18 years of age
- Patients on vitamin D supplementation
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health System The University of Michigan is home to one of the...
Click here to add this to my saved trials
